Physician profile
Jeffrey S Smith
NPI 1124015367
$802.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $195.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $86.22 | 2019-2020 | |
| Amgen INC. | $73.51 | 2019 | |
| Novo Nordisk INC | $60.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.26 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $47.35 | 2019-2020 | |
| Astellas Pharma US INC | $33.36 | 2019 | |
| Lilly USA, LLC | $27.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.85 | 2019 | |
| Amarin Pharma, INC. | $15.84 | 2019 | |
| Pfizer INC. | $13.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.